Literature DB >> 8345223

Microcirculatory functions in systemic sclerosis: additional parameters for therapeutic concepts?

H P Albrecht1, D Hiller, O P Hornstein, S Bühler-Singer, M Mück, M Gruschwitz.   

Abstract

To study the functional reactivity of the cutaneous microcirculation in progressive systemic sclerosis (PSS), hyperemic responses after arterial occlusion (3 min) and during local heating (42 degrees C) were investigated with simultaneous measurements of red blood cell flux and cutaneous oxygen tension (pcuO2) of the skin in female patients (n = 19) with PSS and in healthy female controls (n = 15). Additionally, serum levels of 6-keto-prostaglandin 1 alpha (PGF1 alpha), a stable metabolite of prostacyclin, were compared to the microcirculatory data, and both were used to evaluate further a standardized therapy with 10-d intravenous calcitonin (100 IU/d) infusion in six PSS patients. In PSS, the initial mean pcuO2 value was significantly reduced and was inversely proportional to flux and to PGF1 alpha levels, whereas the flux and pcuO2 responses to the above hyperemic stimuli showed significant reductions, revealing a pattern of "hyperemic hypoxia" probably due to exhausted functional reserves of cutaneous perfusion. During calcitonin infusion significant rises in pcuO2 and temporarily in PGF1 alpha and flux were found. After 10 d of therapy, increased pcuO2 was associated significantly with decreased flux, indicating a shifting of blood from deeper regulatory vessels to the subepidermal capillaries. Both clinical improvement and the results of microcirculatory measurements demonstrate a beneficial effect of calcitonin on the cutaneous microcirculation in PSS patients, possibly due in part to a short-term increase in release of endogenous prostacyclin from the vascular endothelium during the infusion. The disturbed reactivity of the dermal vessels in PSS is important for the evaluation of therapeutic concepts and stresses, together with the elevated PGF1 alpha plasma levels, vascular factors in the pathogenesis of PSS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8345223     DOI: 10.1111/1523-1747.ep12363834

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Deterioration of cutaneous microcirculatory status of Kawasaki disease.

Authors:  Ming-Yii Huang; Joh-Jong Huang; Teh-Yang Huang; Monesha Gupta-Malhotra; Fei-Kai Syu
Journal:  Clin Rheumatol       Date:  2012-02-04       Impact factor: 2.980

2.  Finger skin temperature in patients affected by Raynaud's phenomenon with or without anticentromere antibody positivity.

Authors:  P Caramaschi; D Biasi; A Carletto; T Manzo; M Randon; S Zeminian; L M Bambara
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

3.  Reflexes of the cutaneous microcirculation in amitriptyline and in fluoxetine treated patients.

Authors:  M Mück-Weymann; T Rechlin
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

4.  Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts.

Authors:  K-H Hong; S-A Yoo; S-S Kang; J-J Choi; W-U Kim; C-S Cho
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

5.  Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions.

Authors:  Anthony J Deegan; Faezeh Talebi-Liasi; Shaozhen Song; Yuandong Li; Jingjiang Xu; Shaojie Men; Michi M Shinohara; Mary E Flowers; Stephanie J Lee; Ruikang K Wang
Journal:  Lasers Surg Med       Date:  2018-01-22       Impact factor: 4.025

Review 6.  Systemic and localized scleroderma in children: current and future treatment options.

Authors:  Margalit E Rosenkranz; Lucila M A Agle; Petros Efthimiou; Thomas J A Lehman
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 7.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.